Floatz logo

Vinflunine

Bladder Transitional Cell Carcinoma Stage IV

Pierre Fabre MedicamentSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

38 Active assets in the Bladder Transitional Cell Carcinoma Stage IV cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
Atezolizumab
KaliVir Immunotherapeutics
Phase 3BB
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
Nivolumab
Nagoya University
Phase 3BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Vinflunine is also rated in:

urothelial carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
renal pelvis carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
ureter cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →